rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Corvus Pharmaceuticals, Inc.

CRVS · Nasdaq

Health CareBiotechnologyNot moving yet

CRVS stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 13 weeks. It is 30.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 13
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$667K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
169 (+13)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$9.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
David Scott MooreDirectorbought21,700at $11.5311 Jun 2026filed 15 Jun 2026
Richard A. Md MillerPresident and CEObought5,000at $12.0518 May 2026filed 20 May 2026
Richard A. Md MillerPresident and CEObought1,932at $12.0118 May 2026filed 20 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders169+13 on the quarter
New · exited42 · 28
Reported value$1.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ORBIMED ADVISORS LLCunchanged · filed 14 Aug 20267,165,006$107.0M00.0%
BlackRock, Inc.added · filed 7 Aug 20267,138,811$106.7M+978,389+15.9%
STATE STREET CORPadded · filed 7 Aug 20264,474,091$66.8M+908,099+25.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,292,710$49.2M+58,172+1.8%
ADAMS STREET PARTNERS LLCunchanged · filed 14 Aug 20263,275,616$48.9M00.0%
Vivo Capital, LLCunchanged · filed 14 Aug 20262,805,816$41.9M00.0%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20262,731,632$40.8M+413,115+17.8%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20262,667,441$39.9M+375,000+16.4%
Deep Track Capital, LPadded · filed 14 Aug 20262,491,939$37.2M+4000.0%
BRAIDWELL LPadded · filed 14 Aug 20262,126,298$31.8M+373,500+21.3%
31 Mar 2023 – 30 Jun 2026
3399164Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David Scott Moore Company insiderDirector · last 11 Jun 20261 · 0
Ian T. Clark Company insiderDirector · last 11 Jun 20260 · 0
Linda Grais Company insiderDirector · last 11 Jun 20261 · 0
Peter A. Thompson Company insiderDirector, 10% owner · last 11 Jun 202619 · 2
Richard van den Broek Company insiderDirector · last 11 Jun 20260 · 0
Richard A. Miller Company insiderPresident and CEO · last 18 May 202635 · 0
Andrew C. Chan Company insiderDirector · last 23 Apr 20260 · 0
Jeffrey Arcara Company insiderChief Business Officer · last 4 Dec 20250 · 0
Leiv Lea Company insiderChief Financial Officer · last 4 Dec 20257 · 0
William Benton Jones Company insiderOfficer · last 4 Dec 20252 · 0
ORBIMED ADVISORS LLC Company insiderDirector, 10% owner · last 27 Jun 202513 · 1
Scott W. Morrison Company insiderDirector · last 12 Jun 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-69.6%
Share count trendFY 2025 · to 12 Mar 202612.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.6M
Free cash flowFY 2025 · to 31 Dec 2025−$33.0M

Analyst forecasts

No analyst forecasts yet.